MA28901B1 - Methode de traitement de cancers - Google Patents

Methode de traitement de cancers

Info

Publication number
MA28901B1
MA28901B1 MA29554A MA29554A MA28901B1 MA 28901 B1 MA28901 B1 MA 28901B1 MA 29554 A MA29554 A MA 29554A MA 29554 A MA29554 A MA 29554A MA 28901 B1 MA28901 B1 MA 28901B1
Authority
MA
Morocco
Prior art keywords
treating cancers
cancers
treating
Prior art date
Application number
MA29554A
Other languages
English (en)
Inventor
Mark S Berger
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA28901B1 publication Critical patent/MA28901B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29554A 2004-06-04 2006-12-25 Methode de traitement de cancers MA28901B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57733704P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
MA28901B1 true MA28901B1 (fr) 2007-10-01

Family

ID=35503649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29554A MA28901B1 (fr) 2004-06-04 2006-12-25 Methode de traitement de cancers

Country Status (14)

Country Link
US (1) US20090317383A1 (fr)
EP (1) EP1765344A4 (fr)
JP (1) JP2008501708A (fr)
KR (1) KR20070034536A (fr)
CN (2) CN101564535A (fr)
AU (2) AU2005251769B2 (fr)
BR (1) BRPI0511765A (fr)
CA (1) CA2569139A1 (fr)
IL (1) IL179323A0 (fr)
MA (1) MA28901B1 (fr)
MX (1) MXPA06013952A (fr)
NO (1) NO20066079L (fr)
RU (2) RU2361589C2 (fr)
WO (1) WO2005120512A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306097A1 (en) * 2004-12-17 2008-12-11 Smithkline Beecham (Cork) Limited Cancer Treatment Method
WO2007143483A2 (fr) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Procédé de traitement du cancer
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
CL2007002878A1 (es) 2006-10-06 2008-08-01 Takeda Pharmaceutical Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
EP2088862A4 (fr) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd Méthode de traitement du cancer
US8435752B2 (en) 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
WO2009110415A1 (fr) 2008-03-03 2009-09-11 武田薬品工業株式会社 Médicament concomitant
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010091198A1 (fr) 2009-02-06 2010-08-12 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
US20140302050A1 (en) * 2011-11-09 2014-10-09 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100717916B1 (ko) * 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
CZ299561B6 (cs) * 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
US8211030B2 (en) * 2009-03-26 2012-07-03 The General Electric Company NIBP target inflation pressure automation using derived SPO2 signals

Also Published As

Publication number Publication date
AU2008229859A1 (en) 2008-10-30
BRPI0511765A (pt) 2008-01-08
RU2006142418A (ru) 2008-07-20
RU2008150250A (ru) 2010-06-27
CA2569139A1 (fr) 2005-12-22
EP1765344A4 (fr) 2009-12-02
KR20070034536A (ko) 2007-03-28
CN1984656B (zh) 2010-05-26
US20090317383A1 (en) 2009-12-24
WO2005120512A3 (fr) 2006-04-27
AU2005251769B2 (en) 2008-10-02
WO2005120512A2 (fr) 2005-12-22
EP1765344A2 (fr) 2007-03-28
CN1984656A (zh) 2007-06-20
IL179323A0 (en) 2007-05-15
RU2361589C2 (ru) 2009-07-20
CN101564535A (zh) 2009-10-28
NO20066079L (no) 2007-01-12
AU2005251769A1 (en) 2005-12-22
MXPA06013952A (es) 2007-02-08
JP2008501708A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
MA28901B1 (fr) Methode de traitement de cancers
FR21C1062I1 (fr) Traitement combiné de tumeurs exprimant la cd38
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
BRPI0810206A2 (pt) Método de tratar câncer
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
CR9878A (es) Tratamiento y profilaxis de microangiopatias
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005016127D1 (de) Substituierte hydantoine zur krebsbehandlung
FI20060154A (fi) Neurogeneratiivisten tilojen hoito
EP1991230A4 (fr) Méthodes de traitement du cancer
NO20070251A (no) Brønnbehandling
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
EP1833511A4 (fr) Methode de traitement du cancer du cerveau
MA28691B1 (fr) Procede de traitement du cancer
BRPI0615165A2 (pt) método de tratamento de infertilidade
EP1988060A4 (fr) Procede de traitement d'eau usagee
NO20070042L (no) Behandling av hydrokarboner
EP1871419A4 (fr) Methodes de traitement du rejet d'une greffe contre l'hote
GB0426196D0 (en) Methods of treatment
BRPI0715087A2 (pt) Método de tratamento de disfunção termoregulatória com paroxetina
GB2424579B (en) Method of treating hair